Related Experiment Video
Updated: Dec 26, 2025
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
Molecular targets and novel therapeutic avenues in soft-tissue sarcoma
A Elkrief1,2, T Alcindor1
1Cedars Cancer Centre, Department of Oncology, McGill University Health Centre, Montreal, QC.
Abstract:
Soft-tissue sarcoma (sts) represents a heterogeneous group of rare tumours, and a significant number of affected patients will develop metastatic disease. Outcomes in the population with metastatic disease are generally poor, especially after progression on standard chemotherapy. The advent of personalized medicine has permitted oncologists to offer targeted treatment, thus addressing the limited treatment options and poor prognosis after progression on first-line chemotherapy. In this review, we delineate the existing data and therapeutic successes with respect to existing and emerging molecular targets in sts and options for immunotherapy in sts. Our review also summarizes emerging clinical trials that are currently recruiting patients.
Insights
Soft-tissue sarcoma (STS) is a rare cancer. Personalized medicine offers new targeted treatments and immunotherapies for metastatic STS patients who have progressed on chemotherapy, improving outcomes.
Area of Science:
- Oncology
- Medical Genetics
Background:
- Soft-tissue sarcoma (STS) comprises rare, heterogeneous tumors with a high propensity for metastasis.
- Metastatic STS patients often face poor prognoses, particularly after failing standard chemotherapy.
Purpose of the Study:
- To review current and emerging molecular targets for STS treatment.
- To explore immunotherapy options and ongoing clinical trials in STS.
Main Methods:
- Literature review of existing data on molecular targets in STS.
- Analysis of therapeutic successes and emerging treatment strategies.
- Summary of current clinical trials recruiting STS patients.
Main Results:
- Personalized medicine provides targeted treatment options for advanced STS.
- Emerging molecular targets and immunotherapies show promise for improving outcomes.
- Several clinical trials are actively investigating novel therapies for STS.
Conclusions:
- Targeted therapies and immunotherapies represent a paradigm shift in managing metastatic STS.
- Further research and clinical trials are crucial for optimizing treatment strategies and patient prognosis in STS.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
01:15Drugs that Stabilize Microtubules